URGN 10.64 (-0.65%)
IL0011407140BiotechnologyBiotechnology

UroGen Pharma (URGN) Stock Highlights

10.64 | -0.65%
2024-12-21 05:25:34
UroGen Pharma Ltd is a clinical stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies. The company has an innovative and broad pipeline of product candidates that can overcome the deficiencies of current treatment options for a variety of urological conditions with a focus on uro-oncology. Its lead product candidates, UGN-101 and UGN-102, are proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, a generic drug, which is used off-label for urothelial cancer treatment only in a water-based formulation as an adjuvant, or supplemental post-surgery, therapy.

Statistics

Range Today
10.51 11.08
Volume Today 1.4M
Range 1 Year
10.54 20.7
Volume 1 Year 121.72M
Range 3 Year
4.85 24.13
Volume 3 Year 228.22M
Range 10 Year
4.85 69.568
Volume 10 Year 401.07M

Highlights

Market Capitalization 510.42M (small)
Floating Shares 24.49M
Current Price 10.64
Price To Earnings -3.98
Price To Revenue 4.3
Price To Book 20.03
Earnings Per Share -3.03
Payout Ratio 0%

Performance

Latest -0.65%
1 Month -4.4%
3 Months -23.18%
6 Months -36.67%
1 Year -29.44%
3 Years +10.49%
5 Years -69.5%
10 Years -19.94%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.